Dry powder inhaler developer Iconovo has announced a partnership with McMaster University for development of a dry powder tuberculosis vaccine to be delivered via Iconovo’s ICOone single-dose DPI. According to the company, the ICOone inhaler will “will be used as a test platform to facilitate future commercialization and large-scale manufacturing.”
The 3-year project is partially funded by the Canadian Institutes of Health Research (CIHR) and the Natural Sciences and Engineering Research Council of Canada (NSERC).
Iconovo CEO Orest Lastow commented, “This is a very important first step towards being able to offer a safe, effective and affordable tuberculosis vaccine. We are extremely pleased to collaborate with some of the world’s top researchers in the field and proud they have chosen to work with our ICOone.”
McMaster University Professor Michael Thompson, the project manager, said, “The research team at McMaster, composed of world leading immunologists and engineers who will develop the vaccines, is excited by this opportunity to work with the design talent of Iconovo in inhaler products to address critical deficiencies in global immunization programs as described by the World Health Organization.”
Read the Iconovo press release.
